HighTower Advisors LLC Purchases 624 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

HighTower Advisors LLC boosted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 7.3% in the fourth quarter, HoldingsChannel reports. The firm owned 9,130 shares of the specialty pharmaceutical company’s stock after acquiring an additional 624 shares during the period. HighTower Advisors LLC’s holdings in Supernus Pharmaceuticals were worth $330,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Smartleaf Asset Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 870 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $72,000. Venturi Wealth Management LLC acquired a new position in Supernus Pharmaceuticals during the 4th quarter worth $92,000. KBC Group NV increased its stake in shares of Supernus Pharmaceuticals by 53.1% in the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock valued at $97,000 after buying an additional 929 shares during the period. Finally, Janney Montgomery Scott LLC bought a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth $211,000.

Analyst Upgrades and Downgrades

SUPN has been the subject of several recent research reports. Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,104 shares of company stock valued at $440,263. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN opened at $31.68 on Wednesday. The company has a market capitalization of $1.77 billion, a PE ratio of 29.61 and a beta of 0.84. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The company has a 50 day moving average price of $34.91 and a two-hundred day moving average price of $35.06.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.